Cassava Sciences, Inc. Warrant
SAVAW
NASDAQ Global Market0.03
USD
- -
- -
Return %
Stock
S&P500
1Y
-99.05
26.53
3Y
-99.05
76.60
5Y
-99.05
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Richard Jon Barry
- Full Time Employees
- 30
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 6801 N. Capital of Texas Hwy, Bldg 1 Austin TX United States of America 78731
- IPO Date
- Jan 8, 2024
- Website
- cassavasciences.com
- Similar Companies
- Business
- Cassava Sciences, Inc. is a clinical-stage biotechnology company engaged in the development and commercialization of drugs and diagnostic products for neurodegenerative diseases. The company specializes in therapeutic drug candidates and diagnostic technologies focused primarily on Alzheimer's disease and related neurological conditions. Its main products include simufilam, a small molecule drug that has completed Phase 2 clinical trials and targets Alzheimer's disease by stabilizing and restoring altered protein structures in the brain, and SavaDx, a blood-based biomarker diagnostic designed to detect Alzheimer's disease. Founded in 1998 and headquartered in Austin, Texas, Cassava Sciences operates primarily in the biopharmaceutical sector with a focus on neuroscience. The company transitioned from its former name Pain Therapeutics, Inc. to Cassava Sciences, Inc. in 2019. Cassava has expanded its development pipeline recently, shifting its clinical focus following Phase 3 trial setbacks in Alzheimer's treatment by advancing simufilam into new therapeutic areas. Notably, Cassava Sciences is pursuing a proof-of-concept study for simufilam as a treatment for Tuberous Sclerosis Complex (TSC)-related epilepsy, backed by promising preclinical results showing significant seizure reduction in mouse models. This strategic pivot includes a new licensing agreement with Yale University and appointments of new leadership roles such as a Chief Medical Officer and senior vice presidents specialized in neuroscience and clinical development. In recent developments, Cassava has implemented operational cost reductions including a workforce reduction while securing approximately $117.3 million in cash reserves as of 2025. The company reported a narrowing net loss for Q3 2025 reflecting decreased R&D expenses due to the phaseout of the Alzheimer's program and cost controls. Cassava continues to strengthen its leadership team and refine its pipeline with the intent to initiate clinical trials for simufilam in TSC-related epilepsy by the first half of 2026. These efforts illustrate a significant strategic shift toward expanding its product pipeline beyond Alzheimer's disease into other neuroscientific therapeutic areas. Overall, Cassava Sciences, Inc. presents a focused clinical-stage biotechnology profile with proprietary assets targeting neurodegenerative and neurological disorders, a strategic reorientation driven by recent clinical outcomes, and active pipeline development supported by key partnerships and licensing arrangements in the United States. This description reflects Cassava Sciences' current operations, product offerings, and strategic direction as of late 2025.